Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

66.82 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
Topics Stocks
News headline image
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients ↗
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
News headline image
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025 ↗
Low priced stocks to buy for growth provide great value to investors in the $20 range and are expected to pop before 2025. 
Via InvestorPlace
News headline image
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Why Arrowhead Pharmaceuticals (ARWR) Stock Is Seeing Blue Skies ↗
Arrowhead Pharmaceuticals shares are trading higher by more than 6% during Monday's session. The company announced that it presented preclinical data on ARO-INHBE. 
Via Benzinga
News headline image
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More ↗
Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach. 
Via Benzinga
News headline image
Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday? ↗
Arrowhead Pharmaceuticals announced Phase 3 PALISADE study results showing significant triglyceride reduction in familial chylomicronemia syndrome patients treated with plozasiran. 
Via Benzinga
News headline image
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 ↗
These stocks to buy are expected to double by 2025 and could turn mundane market returns into something bigger with a willingness to bet. 
Via InvestorPlace
News headline image
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q2 2024 ↗
ARWR stock results show that Arrowhead Pharma missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment ↗
Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses... 
Via Benzinga
News headline image
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Turnstone Biologics Appoints William Waddill to its Board of Directors
From Turnstone Biologics Corp.
Via GlobeNewswire
News headline image
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024 ↗
With risk-on sentiment in place, investors may be looking for the most undervalued Russell 2000 stocks to buy in April. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.